Insider Selling: Insmed Incorporated (NASDAQ:INSM) CEO Sells 18,750 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares of the company’s stock, valued at approximately $25,742,347.58. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

William Lewis also recently made the following trade(s):

• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Stock Down 0.2 %

Insmed stock opened at $78.77 on Friday. The stock has a market cap of $14.26 billion, a PE ratio of -14.09 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock’s fifty day moving average is $77.14 and its two-hundred day moving average is $73.77. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, sell-side analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on INSM. Bank of America increased their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday. Truist Financial lifted their target price on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Stifel Nicolaus cut their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $100.00 target price on shares of Insmed in a report on Wednesday. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of INSM. National Bank of Canada FI boosted its stake in Insmed by 9.7% in the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 147 shares in the last quarter. CIBC Asset Management Inc boosted its position in shares of Insmed by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 149 shares during the period. Abel Hall LLC increased its position in Insmed by 4.7% during the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 151 shares during the period. Snowden Capital Advisors LLC lifted its stake in Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 158 shares during the last quarter. Finally, Commerce Bank boosted its holdings in shares of Insmed by 2.4% in the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 163 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.